Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7628406 | 0.73 | TDP1 (0.31) | TDP1 | |
| SCHEMBL28915337 | 0.64 | — | — | |
| SCHEMBL766307 | 0.64 | — | — | |
| SCHEMBL3678505 | 0.64 | — | — | |
| SCHEMBL6528145 | 0.64 | — | — | |
| SCHEMBL28857261 | 0.64 | ALDH1A1 (0.39) | — | |
| SCHEMBL5688490 | 0.64 | ALDH1A1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL11468853 | 0.61 | — | — | |
| SCHEMBL18423818 | 0.61 | — | — | |
| 1,1,2,2-Tetrachloroethane SCHEMBL2564 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104530417-B | A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-08 | — | — | CN | claimed |
| CN-104530415-B | A kind of different functionalization Y types polyethyleneglycol derivative, preparation method and its bio-related substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-01 | — | — | CN | claimed |
| US-20250215037-A1 | ELECTROCHEMICALLY-CLEAVABLE LINKERS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-07-03 | — | — | US | disclosed |
| US-20250215037-A1 | ELECTROCHEMICALLY-CLEAVABLE LINKERS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-07-03 | — | — | US | disclosed |
| US-12281134-B2 | Electrochemically-cleavable linkers | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12281134-B2 | Electrochemically-cleavable linkers | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115635-A1 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-04-10 | — | — | US | disclosed |
| US-20250115635-A1 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-04-10 | — | — | US | disclosed |
| US-12215121-B2 | Linker structures with minimal scar for enzymatic synthesis | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-02-04 | — | — | US | disclosed |
| US-12215121-B2 | Linker structures with minimal scar for enzymatic synthesis | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4355874-A1 | METHODS OF PREPARING BIVALENT MOLECULES | Insitro, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20030224409-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS, INC., A DELAWARE CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030138788-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | US | disclosed |
| US-20020182714-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020172970-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002018540-A2 | PYRIDINE DERIVATIVES USEFUL AS CD40:CD154 BINDING INTERRUPTOR COMPOUNDS AND USE THEREOF TO TREAT IMMUNOLOGICAL COMPLICATIONS | BIOGEN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6207861-B1 | Method for producing and screening mass coded combinatorial libraries for drug discovery and target validation | NEOGENESIS, INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1045819-A1 | METHOD FOR PRODUCING MASS-CODED COMBINATORIAL LIBRARIES | Neogenesis, Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035109-A1 | METHOD FOR PRODUCING MASS-CODED COMBINATORIAL LIBRARIES | NEOGENESIS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| US-4508658-A | Pentahalophenyl ester of cyanoacetic acid derivatives | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115635-A1 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | RNGTT, MMP1, UNG | TDP1 385/4885 |
| US-20250215037-A1 | ELECTROCHEMICALLY-CLEAVABLE LINKERS | RNGTT, DNPEP, DTYMK | TDP1 165/4885 |
| US-12281134-B2 | Electrochemically-cleavable linkers | RNGTT, DNPEP, DTYMK | TDP1 165/4885 |
| US-20030224409-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | TPX2, LPXN, PDHX | TDP1 3967/4885 |
| US-12215121-B2 | Linker structures with minimal scar for enzymatic synthesis | RNGTT, MMP1, UNG | TDP1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.